ZLAB News and Press, Zai Lab Limited From 11/08/22

SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal immuno-oncology pipeline at the upcoming Society for Immuno...

Zai Lab ( NASDAQ: ZLAB ) shares are up 4% in pre-market trading on Tuesday following a leadership change that sees Dr. Peter Huang named as company's new chief scientific officer. The appointment is effective immediately, the Chinese biotech company said . Hua...

SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Dr. Peter Huang as its Chief Scientific Officer (CSO), effective ...

Summary Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of man...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following in...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for t...

Zai Lab is committed to earning your trust through our environmental, social, and governance (ESG) strategy, which we are calling Trust for Life Zai’s Trust for Life strategy includes three commitments to improve human health, create better outcomes, and act rig...

Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing CAGR. Cervical Cancer is a cancer arising from the cervix w...

Summary Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the Nasdaq Exchange at a pre-money equity value of $834 million. Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to ...

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and ...